Sigma-Aldrich Names David A. Smoller New VP of Research and Development

11-Jun-2004

Sigma-Aldrich Corporation is pleased to announce that David A. Smoller, Ph.D., has been named the Vice President of R&D, effective June 1, 2004. In this role, he will help expand Sigma-Aldrich's leadership position through the development of new and innovative products for Life Science and High Technology research.

Dr. Smoller brings a variety of experience to Sigma-Aldrich. Most recently he was CEO and President of ProteoPlex, a seed stage spinout focusing on functional genomics. Dr. Smoller founded ProteoPlex in 2001 and led the St. Louis-based company through its product development and final acquisition.

In 1992, Dr. Smoller founded Genome Systems, Inc., in St. Louis, which provided the scientific community with access to genome project-related technologies. Dr. Smoller stayed at the helm of the organization until it was acquired in 1996 by the Incyte Corporation, based in Palo Alto, California. Dr. Smoller joined Incyte as Vice President eventually becoming Senior Vice President and leader of the St. Louis organization growing the staff to more than 250 people.

During his tenure at Incyte, his responsibilities included managing the Genomics Business Unit, with over $150 million in annual sales, as well as strategic planning, product marketing, and research and development strategy. His depth of experience is expected to be a valuable asset to Sigma-Aldrich's R&D organization.

Dr. Smoller earned a doctorate degree in Molecular Biology and a bachelor's degree in Biology from Emory University in Atlanta, Georgia. He completed a postdoctoral fellowship at Washington University in the Drosophila Genome project and a postdoctoral fellowship at Monsanto Corporation. He will be based at Sigma-Aldrich's Life Science and High Technology Center in St. Louis.

https://www.chemeurope.com/en/news/37981/sigma-aldrich-names-david-a-smoller-new-vp-of-research-and-development.html